Patents by Inventor Thais Motria Sielecki-Dzurdz

Thais Motria Sielecki-Dzurdz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR SYNTHESIZING D3 DOPAMINE RECEPTOR AGONISTS
    Publication number: 20220009876
    Abstract: An improved method for synthesizing a compound according to formula (I) by reaction of a compound of formula (II) with a sulfinamide according to formula (III). The resultant compound is then reduced and hydrolyzed, and optionally alkylated or arylated to arrive at the compound according to formula (I).
    Type: Application
    Filed: October 31, 2019
    Publication date: January 13, 2022
    Inventors: Thais Motria SIELECKI-DZURDZ, Baoyu Ml, Huiping ZHAO, Sandhya KORTAGERE
  • Pyridino and pyrimidino pyrazinones
    Patent number: 7067658
    Abstract: The present invention provides compounds of Formula I: wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 27, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thais Motria Sielecki-Dzurdz, Argyrios George Arvanitis, Carolyn Diane Dzierba
  • Pyridino and pyrimidino pyrazinones
    Publication number: 20040082784
    Abstract: The present invention provides compounds of Formula I: 1
    Type: Application
    Filed: September 26, 2003
    Publication date: April 29, 2004
    Inventors: Thais Motria Sielecki-Dzurdz, Argyrios George Arvanitis, Carolyn Diane Dzierba
  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Isoxazoline and isoxazole fibrinogen receptor antagonists
    Patent number: 5849736
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa